About the Campaign
The Campaign for Patient Access was launched by the American College of Cardiology in December 2009 as a national effort to reverse Medicare physician fee schedule cuts that threatened cardiovascular care. The site provided background on the issue, the ACC's legislative and legal response, resources for patients and practices, a newsroom tracking coverage across the country, and ways for supporters to share their stories and support the campaign.
From the Newsroom
Medicare Meltdown: Access to Health Care in "Critical Condition"
A press release warning that cardiology access was in critical condition due to Medicare payment cuts.
Read more
Cardiology Takes Legal Action Against Medicare
The ACC filed suit against HHS Secretary Kathleen Sebelius over the 2010 Physician Fee Schedule.
Read more
ACC Statement on Health Care Reform
The ACC used the State of the Union address to highlight the need to reverse the Medicare cuts.
Read more
Medicare Patients and Physicians Join Petition Drive
Patients and physicians in Washington, DC joined a petition drive calling on Congress for Medicare reform.
Read moreWhen fee cuts restrict access to heart rhythm monitors
Wearable cardiac monitoring devices—prescribed ECG patches, Holter monitors and event recorders—help clinicians detect arrhythmias that a brief clinic visit may miss. The impact of cuts on access to these devices is not simply about hardware. If payments for arranging tests, reading recordings, reporting results and follow-up fall, patients can encounter longer waits, fewer monitoring episodes or less time with a cardiologist. The policy issue concerns the US Medicare physician fee schedule, distinct from Australia’s Medicare.
For people with suspected atrial fibrillation, intermittent palpitations or other rhythm symptoms, delay can postpone treatment decisions and leave risks unassessed. For cardiology practices, cuts can mean constrained staffing and a weaker business case for niche monitoring. Australian readers should also distinguish prescribed medical-grade monitoring from consumer smartwatches and chest straps sold for fitness. Their growing role is useful, but it does not reproduce a diagnostic pathway built around symptoms, risk and clinical review.
From a device to a complete diagnostic pathway
Prescribed wearable cardiac monitors are not single-use gadgets bought off a shelf. A patient may need a referral, a fitting, delivery, instructions, technical support, specialist interpretation and a plan for the result. The device captures the signal, but the surrounding service determines whether the recording reaches the right clinician in useful time. Payment cuts can land on any of those steps.
Lower clinician payments may change which tests are offered, how quickly they are scheduled, and whether practices keep enough staff to review data outside consulting hours. Event recorders for infrequent symptoms can be vulnerable if follow-up becomes less remunerated, even when the device remains affordable. A shorter or more selective monitoring period can also produce an inconclusive result, leading to another appointment and more delay.
These effects need qualification. A fee cut does not automatically make a device unavailable, and high demand can sometimes keep practices busy regardless of price. The concern is the accumulated effect across capacity, triage and participation: patients who can wait or pay privately may absorb the difference, while people relying on public services bear more of the burden.
Why payment pressure changes monitoring behaviour
The financial chain begins with the clinician, not the manufacturer. Prescribing a suitable test, checking whether the recording is adequate and explaining an abnormal result all take trained time. If consultation and interpretation payments fall, practices may limit after-hours review, use stricter criteria for intermittent-event devices or defer discussions needing extra follow-up. Each response is manageable; together they can reduce the volume and timeliness of monitoring.
Hospitals and community practices carry downstream costs. Longer waits consume outpatient slots, while repeated or inconclusive tests use staff, electrodes and clinic space. Unclear results can lead people to private urgent care, creating out-of-pocket costs and pressure on emergency departments. These are access harms even when the reimbursement rule appears concerned only with Medicare pricing.
Cutting reimbursement can affect care through behaviour rather than a formal device ban, which makes evidence important. Campaigners should compare referral numbers, waiting times, abandonment rates, report turnaround and treatment delays before and after policy changes, while separating correlation from cause. Patient accounts can explain what delay means in daily life: another week of uncertainty, an episode that cannot be reconstructed, or a referral returned for another test.
What this means for Australian patients
Australia’s Medicare is a different system: the Commonwealth and states fund public hospital and outpatient services, while Services Australia administers Medicare benefits under the Medicare Benefits Schedule. General practitioners coordinate many pathways, and a GP referral commonly leads to a cardiologist, diagnostic service or public outpatient clinic. A US fee schedule dispute does not change an Australian rebate, but it warns what happens when the people who order, interpret and act on tests are underpaid.
The Australian monitoring market mixes public hospital services, private cardiology and diagnostic businesses, and consumer products sold through pharmacies, electrical retailers and online marketplaces. Patients may hear the term “holter” for a worn ECG monitor, or “heart-rhythm monitor” for an event recorder. Shopping for a cheaper gadget can appear to solve a referral problem, although a consumer reading cannot establish the same diagnostic value as prescribed monitoring with clinical interpretation.
Distance sharpens the issue. In rural New South Wales, northern Queensland and remote Northern Territory communities, a device may need fitting through a local health service, posting to a cardiology centre, telehealth support and return for review. Travel, broadband limits, postal delays and shortages of local technicians can turn a straightforward pathway into a practical barrier. Co-design with Aboriginal and Torres Strait Islander health services can identify safer ways to deliver equipment, explain results and support consent.
Why law and legislation shape the response
The American College of Cardiology’s Campaign for Patient Access frames litigation and legislation as complementary tools in opposing cuts. Its legal strategy guide explains the legal strategy behind challenging Medicare fee schedule cuts, including the administrative record and the arguments used to connect arbitrary reductions to access harms. For advocates, the value of litigation is not publicity alone; it can force agencies and decision-makers to confront the evidence assembled by patients, clinicians and independent researchers.
Legal action must be matched to the legal framework. Courts generally assess whether agency procedure was lawful and whether the decision was reasoned; patients and clinicians can show concrete harms through stories, wait-time data and records of interrupted care. Legislative oversight can then address gaps that litigation cannot, such as reimbursement methodology, reporting duties or temporary continuity measures.
For Australian stakeholders, the parallel is a policy process rather than copied litigation. Clinicians and patients can make submissions on Medical Benefits Schedule changes, give evidence to parliamentary committees, and ask federal and state ministers for transparent access measures. Public hospital leaders can quantify unused monitoring capacity and delayed results, while private providers can document how reimbursement affects participation. Campaign news and patient stories can connect those local facts to a broader public-interest case.
Using wearable evidence safely
Monitoring carries safety and governance questions. The Therapeutic Goods Administration regulates medical devices in Australia, and consumers should check whether a product’s specific claims place it on the Australian Register of Therapeutic Goods. A fitness tracker’s pulse alert or single-lead ECG is not a substitute for prescribed ambulatory ECG. Sudden chest pain, severe breathlessness, fainting or a sustained irregular heartbeat warrants prompt medical advice rather than continued app-based observation.
Cloud-based devices create another consideration. Patients should ask where data is stored, who can view it, how long it is retained and whether it can be shared with their treating team. Clear consent matters when a device also supports convenience alerts, mental-health features or advertising. A clinician receiving a hurried, unverified alert may spend longer sorting information, while a patient may wrongly interpret a notification as a diagnosis.
The strongest approach combines appropriate patient selection, high-quality electrodes, enough wear time, prompt transmission, specialist review and a documented follow-up plan. These elements are particularly important for detecting intermittent events. A report that is technically complete but arrives after symptoms have resolved may still fail patients if no clinician has time to act on it.
A practical campaign for timely access
Campaign for Patient Access works best when technical policy is paired with clear patient experience. Patients, clinicians, practice managers, policymakers and media partners in Australia can advance these priorities:
- Protect reimbursement for prescribing, fitting, interpreting and following up ambulatory ECG monitoring.
- Require public and private providers to publish appointment waits, no-show rates and time from recording to review.
- Fund fittings, courier logistics and telehealth for rural and remote patients rather than treating the monitor as a standalone product.
- Publish a pathway showing who fits a monitor, receives data, gives results and handles urgent findings.
- Make clear that consumer wearables can support awareness but cannot replace prescribed testing or interpretation.
- Build patient stories into consultations, submissions and public reporting without exposing personal health information.
These measures turn an abstract fee dispute into observable service standards and create evidence for legislative review. A rising no-show rate after a price change may signal that patients cannot afford travel or time away from work, while delayed reports may show squeezed interpretation capacity. Practices can use the framework to support fair access without treating every patient as either low priority or a commercial opportunity.
Australians concerned about heart-rhythm monitoring can start with their GP or cardiologist, record the dates and delays they experience, and ask where a prescribed monitor will be fitted and who will review it. They can also share a consented account with patient groups, write to their federal or state representative and ask policymakers for transparent access data. The campaign’s purpose is practical: keep clinically necessary monitoring available, timely and connected to care.
Campaign for Patient Access